Vitamin C Levels in Critically Ill COVID-19 Patients

Vitamin C Levels in Critically Ill COVID-19 Patients

by Michael Passwater

 

From the COVID-19 pandemic, we continue to learn about the critical importance of maintaining adequate levels of essential nutrients. When the body is under stress from an illness such as an infection, merely eating an excellent diet may not provide sufficient nutrients to support the immune system. To stave off a fast-moving infection may require higher levels of essential vitamins and minerals. Vitamin C has an essential role in empowering the immune system. Its oxidized form can be recycled by red blood cells (erythrocytes), but a fast-moving illness can overpower this system, causing vitamin C levels to precipitously drop.

A recent study in Spain measured plasma vitamin C levels in 67 critically ill hospitalized adult COVID-19 patients meeting the Berlin criteria for acute respiratory distress syndrome (ARDS).1 The results fell into three categories: undetectable (<0.1 mg/dL), low (0.1 – 0.4 mg/dL), and “normal” (0.4 – 2 mg/dL). Twelve (18%) patients had undetectable plasma vitamin C, 43 (64%) patients had low levels of plasma vitamin C (mean for this group was 0.14 mg/dL with a standard deviation of 0.05), and 12 (18%) patients had vitamin C levels within the normal range (mean for this group was 0.59 mg/dL with a standard deviation of 0.18). In summary, 82% of patients had low or undetectable plasma vitamin C levels, and 18% had values within the reference range, mostly on the low side of the reference range. (Riordon Clinic Bio-Center Laboratory has an established reference range of 0.6 – 2.0 mg/dL for plasma vitamin C). A smaller study of 18 adult COVID-19 patients with ARDS found similar results: 17 (94%) patients had undetectable plasma vitamin C, and 1 (6%) patient had a plasma vitamin C level of 0.24 mg/dL.2 The assay used in this study had a lower limit of detection of 0.15 mg/dL, above the mean of the low-level group in the first study.

Finding low levels of vitamin C in critically ill patients is not new and has been reported in a variety of studies over the last several decades. In 2017, a study of 44 critical care patients receiving recommended amounts of enteral and parenteral vitamin C (125 +/- 88 mg/day, max 448 mg/day) showed 70% of patients had vitamin C deficiency.3 Among septic shock patients, 90% had vitamin C deficiency. Borrelli et al published findings in 1996 showing that the lower the plasma ascorbic acid level in septic patients the greater the risk of organ failure and death.4 Even in presumed healthy people in the USA, vitamin C deficiency is found. In 2003-2004, NHANES samples from noninstitutionalized civilians found a vitamin C deficiency prevalence of 7.1% +/- 0.9%.5 This was a 44% reduction in vitamin C deficiency from the 1988 – 1994 national study. Smoking and low income were associated with higher rates of vitamin C deficiency. People in a deficient state can avoid acute illness for a time but have impaired capacity to respond to infections and other stress challenges.

Why Critically Ill People Require More Vitamin C to Maintain Adequate Levels of Plasma Vitamin C

Increased consumption. White blood cells, such as neutrophils and monocytes, actively take up ascorbic acid from plasma (fluid portion of blood) to achieve intracellular levels of 1 mM, 50-100 -fold higher than the typical vitamin C level of plasma. When stimulated to produce an oxidative burst, these white blood cells will pull in more vitamin C to increase intracellular concentrations ten-fold to 10 mM. If there is not enough vitamin C available, the white blood cell’s oxidative burst intended to kill an invading pathogen may destroy the WBC itself instead. Cytokines, inflammation, fever, and other biological stresses of illness also increase the metabolic demand for vitamin C throughout the body.6

Decreased recycling of dehydroascorbic acid (DHAA) back to ascorbic acid (AA). Healthy blood plasma must contain antioxidants to counteract the effects of oxygen. Ascorbic acid (AA) is a major antioxidant which serves to maintain the reductive capacity of circulating blood.7 AA has a short half-life of minutes in human blood before being oxidized to dehydroascorbic acid (DHAA). Humans cannot make their own ascorbic acid. However, survival is possible with meager milligram amounts of AA intake due to recycling of the oxidized DHAA back to AA within red blood cells (RBCs) in the circulatory system and between astrocytes and tanycytes with GLUT1-DHAA receptors and neurons with SVCT2-AA receptors in the central nervous system. RBCs are the most numerous cell type in the body and have a large number of GLUT1 receptors that preferentially take in DHAA. With 20-30 trillion RBCs circulating in a healthy person, DHAA in the blood can be recycled to AA every three minutes in a healthy person.

Vitamin C (ascorbic acid) is oxidized to dehydroascorbic acid, which can be reduced back to ascorbic acid (vitamin C).

The recycling process is primarily dependent on glutathione peroxidases (GPx, a family of antioxidant selenoproteins), and to a lesser extent on NADH and NADPH oxidoreductases within the red blood cells. Damage or destruction of the RBCs, damage to or shortage of the intracellular reducing agents, or hypoxic conditions impair or halt the recycling process.8,9 Additionally, as the reductive capacity of plasma decreases, the amount of DHAA lost to irreversible oxidation to 2,3-diketo-L-gulonic acid further depletes the body’s pool of AA. To maintain AA levels in the body as intracellular recycling decreases, intake of AA must increase.

In addition to maintaining antioxidant capacity, RBCs are responsible for the management of the three gases of life, O2, CO2, and NO, throughout the body.10 RBCs (erythrocytes) are produced from erythroid precursor cells in the bone marrow and circulate for approximately four months. They are biconcave discs, with very flexible membranes to allow them to flow smoothly throughout the body’s 60,000 miles of blood vessels. Capillaries in the body’s extremities become so narrow that the RBCs flow single file, underscoring the necessity of cell membrane flexibility.

RBC Membrane Components, Interferon, and Selenoproteins

New research reveals that RBC membrane components, interferon, and selenoproteins are targets of the SARS-CoV-2 virus, and along with NAD are all depleted by the virus.11-15 In addition to GLUT1 receptors, RBC membranes also can express ACE2 receptors, which are well established as a cellular entry point for the SARS-CoV-2 virus. CD147 and the RBC structural protein Band3 have also been shown to serve as attachment points for the virus. Mature RBCs do not have a nucleus and cannot support viral replication. However viral attachment and entry can disrupt the RBC’s ability to transport and transfer oxygen to tissues, as well as destroy selenoproteins which in turn disrupts DHAA – AA recycling. RBC membrane disturbances and loss of antioxidant capacity results in a more spherical and less flexible RBC, and oxidation causes phosphatidyl serine and other lipids to flip from the inner side of the membrane to the outer side of the membrane. These changes inhibit the RBC from bending and twisting to travel through the small capillaries of the circulatory system, and accelerate the RBC’s clearance from circulation by the reticuloendothelial system monocytes in the spleen and liver. Immature RBC precursor cells have a nucleus, numerous ACE2 receptors, and can support viral replication. Invasion of these cells by the SARS-CoV-2 virus is even more damaging. Release of RBC precursor cells into the blood stream in response to hypoxia, can intensify the disease by causing immunosuppression and serving as a rich source of selenocysteine and other nutrients for the rapidly replicating virus. The virally induced structural, functional, and metabolic damage to RBCs helps explain cases of COVID-19 presenting with hypoxia disproportional to the degree of pneumonia present.

In addition to elucidating the interactions of SARS-CoV-2 with the RBCs and RBC precursor cells, recent genetics, proteomics, metabolomics, and lipidomics research has identified specific interactions leading to interferon and selenoprotein destruction and suppression. These studies have also identified nicotinamide phosphoribosyltransferase, nicotinamide, and nicotinamide riboside as therapeutic options to boost innate immunity and counteract NAD depletion by the virus.

Importance of Adequate Niacin, Glutathione/Cysteine (NAC and alpha lipoic acid), and Selenium

The findings of recent studies on the effect of nutrient deficiencies in COVID-19 add empirical evidence in support of hypotheses published early in the pandemic. In March of 2020, Yufang Shi and team in China recommended the use of niacin (vitamin B3) whenever lung damage was detected by CT scan.16 Miller, Wentzel, and Richards in South Africa pointed to the importance of NAD+ deficiency.17 Over a decade ago, Ethan Will Taylor proposed the oxidative stress-induced niacin sink (OSINS) model for HIV, another RNA virus.18 Taylor, along with Hiffler, Vavougios, Polonikov and others also suggested glutathione and selenium as central in the etiology of SARS-CoV-2 disease.19-21 Additionally, a German study showed an inverse association between COVID-19 mortality or severe illness and selenium and selenoprotein P levels.22 And in the USA, two cases of severe COVID-19 were successfully treated with oral and intravenous glutathione, N-acetyl-cysteine (NAC), and lipoic acid have been published.23